New Opportunities For VC-Backed Life Sciences Cos.
June 5, 2013, 1:04 PM EDT
Law360, New York (June 5, 2013, 1:04 PM EDT) -- The insatiable funding requirements of early-stage life sciences companies demand an unending and time-consuming quest for capital. Inevitably, the path leads to the door of venture capital firms, which have been a traditional source of financing for drug discovery, drug development, diagnostics and other capital-intensive life sciences businesses. However, the bar to raising venture capital, as well as the cost of that capital, continues to rise.
As a result, companies are devoting ever-increasing efforts to secure alternative nondilutive sources of funding from governmental agencies, patient advocacy...
Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.